Clinical Handbook of Psychotropic Drugs for Children and Adolescents

Quick and comprehensive information on psychotropic drugs for children and adolescents. – Accurate and up-to-date – Specific to children and adolescents – Charts and tables help decision-making – Icons and full color
The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a standard reference and working tool for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals. • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options • Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, nursing implications, and much more – all you need to know for each class of drug • Potential interactions and side effects summarized in comparison charts • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek • Clearly written patient and caregiver information sheets for download as printable PDF files
This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition: • New chapters on Prescribing Safely and Ethically to Children and Adolescents, Pharmacogenetic Information for Common Psychotropic Drugs, and Aggression Management in Children and Adolescents • Neuroscience-based nomenclature added to Product Availability tables • Antipsychotic-Induced Extrapyramidal Side Effect (EPSE) completely revised plus new section on monitoring scales for EPSE • Anxiolytics section on buspirone and benzodiazepine comparison table revised • Mood Stabilizers chapter extensively revised • Natural Health Products comprehensively revised • New Unapproved Treatments revised, including preliminary evidence for cannabidiol and folinic acid for autism spectrum disorder and ketamine for mood disorder • New agents include: deutetrabenazine, ethopropazine, lemborexant, lumateperone, orphenadrine, tetrabenazine, valbenazine, viloxazine • New formulations and trade names include: Austedo, Caplyta, Dayvigo, Drizalma Sprinkle, Elepsia XR, Eprontia, Evekeo ODT, Gocovri, Hetlioz LQ, Ingrezza, Invega Hafyera, Jornay PM, Loreev XR, Lybalvi, Osmolex ER, Oxtellar XR, Parsitan, Perseris, Qelbree, Qudexy XR, Secuado, Spritam, Tyrvaya, Valtoco